Epigenetic regulation in RCC: Opportunities for therapeutic intervention?

Nature Reviews Urology

Volumn 9, Issue 3, 2012, Pages 147-155

  Larkin, James ^a   Goh, Xin Yi ^b   Vetter, Marcus ^a   Pickering, Lisa ^a   Swanton, Charles ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; B RAF KINASE; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; HYDROLYASE; INTERLEUKIN 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RAS PROTEIN; ROMIDEPSIN; SUNITINIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR EZH2; VON HIPPEL LINDAU PROTEIN; VORINOSTAT;

ADVANCED CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CELL HETEROGENEITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN; CHROMOSOME 3; CHROMOSOME 7; CITRIC ACID CYCLE; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DNA TRANSCRIPTION; DRUG MEGADOSE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC REGULATION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; KIDNEY CARCINOMA; LEIOMYOMATOSIS; LUNG CARCINOMA; PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; CARCINOMA, RENAL CELL; EPIGENESIS, GENETIC; GENE REGULATORY NETWORKS; GENES, TUMOR SUPPRESSOR; GENETIC THERAPY; HISTONES; HUMANS; KIDNEY NEOPLASMS; MUTATION;

EID: 84858294880     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.236     Document Type: Review

References (114)

1. Jemal, A. et al. Global cancer statistics, 2010. CA Cancer J. Clin. 61, 69-90 (2011).
2. Mathew, A., Devesa, S. S., Fraumeni, J. F. Jr & Chow, W. H. Global increases in kidney cancer incidence, 1973-1992. Eur. J. Cancer Prev. 11, 171-178 (2002). (Pubitemid 34478435)
3. Sun, M. et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 59, 135-141 (2011).
4. Lam, J. S., Leppert, J. T., Belldegrun, A. S. & Figlin, R. A. Novel approaches in the therapy of metastatic renal cell carcinoma. World J. Urol. 23, 202-212 (2005). (Pubitemid 41136043)
5. Fisher R. A. et al. Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. J. Clin. Oncol. 29, e241-e242 (2011).
6. Lopez-Beltran, A., Scarpelli, M., Montironi, R. & Kirkali, Z. 2004 WHO classification of the renal tumors of the adults. Eur. Urol. 49, 798-805 (2006).
7. Storkel, S. et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80, 987-989 (1997).
8. Renshaw, A. A. Subclassification of renal cell neoplasms: an update for the practising pathologist. Histopathology 41, 283-300 (2002). (Pubitemid 35279025)
9. Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004). (Pubitemid 46646218)
10. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
11. Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16, 68-73 (1997). (Pubitemid 27198158)
12. Alam, N. A. et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 12, 1241-1252 (2003). (Pubitemid 36722604)
13. Alam, N. A. et al. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. J. Mol. Diagn. 7, 437-443 (2005). (Pubitemid 41479710)
14. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 30, 406-410 (2002).
15. Hong, S. B. et al. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling. Mol. Cancer 9, 160 (2010).
16. Toro, J. R. Birt-Hogg-Dubé syndrome. In GeneReviews (eds Pagon, R. A., Bird, T. D., Dolan, C. R. & Stephens, K.) (2008).
17. Schmidt, L. S. et al. Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. Am. J. Hum. Genet. 76, 1023-1033 (2005). (Pubitemid 40705436)
18. Khoo, S. K. et al. Inactivation of BHD in sporadic renal tumors. Cancer Res. 63, 4583-4587 (2003). (Pubitemid 36951033)
19. Argani, P. et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am. J. Surg. Pathol. 31, 1149-1160 (2007). (Pubitemid 47207116)
20. Ross, H. & Argani, P. Xp11 translocation renal cell carcinoma. Pathology 42, 369-373 (2010).
21. van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41, 521-523 (2009).
22. Hurst, F. P. et al. Incidence, predictors and associated outcomes of renal cell carcinoma in long-term dialysis patients. Urology 77, 1271-1276 (2011).
23. Strumberg, D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J. Clin. Oncol. 26, 3469-3471 (2008).
24. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134, (2007). (Pubitemid 46089673)
25. Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
26. Coppin, C. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews, Issue 1. Art No.: CD001425. http://dx.doi.org/ 10.1002/14651858.CD001425.pub2 (2005).
27. Yagoda, A., Petrylak, D. & Thompson, S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am. 20, 303-321 (1993). (Pubitemid 23154480)
28. Rini, B. I. Metastatic renal cell carcinoma: many treatment options, one patient. J. Clin. Oncol. 27, 3225-3234 (2009).
29. Horiuchi, A. et al. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res. 22, 2697-2702 (2002). (Pubitemid 36069300)
30. Harada, H. et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose-and reoxygenation-dependent manner in irradiated tumors. J. Biol. Chem. 284, 5332-5342 (2009).
31. Rini, B. I., Campbell, S. C. & Escudier, B. Renal cell carcinoma. Lancet 373, 1119-1132 (2009).
32. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
33. Motzer, R. J. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116, 4256-4265 (2010).
34. Swanton, C. et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med. 2, 53 (2010).
35. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
36. Muhlbauer, B. et al. Magnesium-L-aspartate-HCl and magnesium-oxide: bioavailability in healthy volunteers. Eur. J. Clin. Pharmacol. 40, 437-438 (1991).
37. Geiman, T. M. & Robertson, K. D. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J. Cell Biochem. 87, 117-125 (2002).
38. Doerfler, W. et al. Eukaryotic DNA methylation: facts and problems. FEBS Lett. 268, 329-333 (1990). (Pubitemid 20241337)
39. Nojima, D. et al. CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol. Carcinog. 32, 19-27 (2001).
40. Morris, M. R. et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29, 2104-2117 (2010).
41. Cooper, G. M. The Cell (Boston University, Sunderland: Sinauer Associates, 2000).
42. Paranjape, S. M., Kamakaka, R. T. & Kadonaga, J. T. Role of chromatin structure in the regulation of transcription by RNA polymerase II. Annu. Rev. Biochem. 63, 265-297 (1994). (Pubitemid 24218635)
43. Grunstein, M. Histone acetylation in chromatin structure and transcription. Nature 389, 349-352 (1997). (Pubitemid 27415209)
44. Horn, P. J. & Peterson, C. L. Molecular biology. Chromatin higher order folding-wrapping up transcription. Science 297, 1824-1827 (2002). (Pubitemid 35024334)
45. Kurdistani, S. K. Histone modifications in cancer biology and prognosis. Prog. Drug Res. 67, 91-106 (2011).
46. Sims, R. J. 3rd, Nishioka, K. & Reinberg, D. Histone lysine methylation: a signature for chromatin function. Trends Genet. 19, 629-639 (2003). (Pubitemid 37338383)
47. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12, 599-606 (1998). (Pubitemid 28134293)
48. Bartova, E., Krejci, J., Harnicarova, A., Galiova, G. & Kozubek, S. Histone modifications and nuclear architecture: a review. J. Histochem. Cytochem. 56, 711-721 (2008). (Pubitemid 351991084)
49. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007). (Pubitemid 46273577)
50. Ruthenburg, A. J., Li, H., Patel, D. J. & Allis, C. D. Multivalent engagement of chromatin modifications by linked binding modules. Nat. Rev. Mol. Cell Biol. 8, 983-994 (2007). (Pubitemid 350174643)
51. Bird, A. Perceptions of epigenetics. Nature 447, 396-398 (2007). (Pubitemid 46816744)
52. Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10, 457-469 (2010).
53. Bannister, A. J., Schneider, R. & Kouzarides, T. Histone methylation: dynamic or static? Cell 109, 801-806 (2002). (Pubitemid 34785995)
54. Martin, C. & Zhang, Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838-849 (2005). (Pubitemid 41568733)
55. Di Lorenzo, A. & Bedford, M. T. Histone arginine methylation. FEBS Lett. 585, 2024-2031 (2011).
56. Lee, D. Y., Teyssier, C., Strahl, B. D. & Stallcup, M. R. Role of protein methylation in regulation of transcription. Endocr. Rev. 26, 147-170 (2005).
57. Berger, S. L. The complex language of chromatin regulation during transcription. Nature 447, 407-412 (2007). (Pubitemid 46816746)
58. Ruthenburg, A. J., Allis, C. D. & Wysocka, J. Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol. Cell 25, 15-30 (2007). (Pubitemid 46049068)
59. Klose, R. J. & Zhang, Y. Regulation of histone methylation by demethylimination and demethylation. Nat. Rev. Mol. Cell Biol. 8, 307-318 (2007). (Pubitemid 46474659)
60. Hess, J. L. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10, 500-507 (2004). (Pubitemid 39303623)
61. Barrett, A. et al. Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int. J. Cancer 121, 265-275 (2007). (Pubitemid 46917694)
62. Xiang, Y. et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc. Natl Acad. Sci. USA 104, 19226-19231 (2007).
63. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003). (Pubitemid 37205983)
64. Simon, J. A. & Lange, C. A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647, 21-29 (2008).
65. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
66. Wagener, N. et al. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int. J. Cancer 123, 1545-1550 (2008).
67. Ougolkov, A. V., Bilim, V. N. & Billadeau, D. D. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin. Cancer Res. 14, 6790-6796 (2008).
68. Chase, A. & Cross, N. C. Aberrations of EZH2 in cancer. Clin. Cancer Res. 17, 2613-2618 (2011).
69. Beyer, S., Kristensen, M. M., Jensen, K. S., Johansen, J. V. & Staller, P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem. 283, 36542-36552 (2008).
70. Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837 (2007). (Pubitemid 46802390)
71. Martinez-Garcia, E. & Licht, J. D. Deregulation of H3K27 methylation in cancer. Nat. Genet. 42, 100-101 (2010).
72. Bannister, A. J. et al. Spatial distribution of di-and tri-methyl lysine 36 of histone H3 at active genes. J. Biol. Chem. 280, 17732-17736 (2005). (Pubitemid 41389011)
73. Huang, J. et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J. Biol. Chem. 285, 9636-9641 (2010).
74. Yamane, K. et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol. Cell 25, 801-812 (2007). (Pubitemid 46436533)
75. Reisman, D., Glaros, S. & Thompson, E. A. The SWI/SNF complex and cancer. Oncogene 28, 1653-1668 (2009).
76. Xia, W. et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 68, 1667-1674 (2008). (Pubitemid 351416550)
77. Burrows, A. E., Smogorzewska, A. & Elledge, S. J. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc. Natl Acad. Sci. USA 107, 14280-14285 (2010).
78. Janssen, A., Kops, G. J. & Medema, R. H. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc. Natl Acad. Sci. USA 106, 19108-19113 (2009).
79. Birkbak, N. J. et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 71, 3447-3452 (2011).
80. Kenneth, N. S., Mudie, S., van Uden, P. & Rocha, S. SWI/SNF regulates the cellular response to hypoxia. J. Biol. Chem. 284, 4123-4131 (2009).
81. Guo, G. et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat. Genet. 44, 17-19 (2012).
82. Morita, R. et al. Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. Cancer Res. 51, 5817-5820 (1991).
83. Flaig, T. W. et al. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br. J. Cancer 103, 796-801 (2010).
84. Bukowski, R. M. et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536-4541 (2007). (Pubitemid 350035309)
85. Jermann, M. et al. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother. Pharmacol. 57, 533-539 (2006). (Pubitemid 43087597)
86. Ravaud, A. et al. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. J. Clin. Oncol. 26, 2285-2291 (2008).
87. Shand, N. et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. 10, 2325-2335 (1999). (Pubitemid 29459843)
88. Buchner, A. et al. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 21, 285-297 (2010).
89. Birkbak, N. J. et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 71, 3447-3452 (2011).
90. Roylance, R. et al. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol. Biomarkers Prev. 20, 2183-2194 (2011).
91. Moch, H. et al. Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization. Cancer Res. 58, 2304-2309 (1998). (Pubitemid 28252683)
92. Li, G. et al. Different DNA ploidy patterns for the differentiation of common subtypes of renal tumors. Cell Oncol. 27, 51-56 (2005). (Pubitemid 40387192)
93. Ljungberg, B., Mehle, C., Stenling, R. & Roos, G. Heterogeneity in renal cell carcinoma and its impact no prognosis-a flow cytometric study. Br. J. Cancer 74, 123-127 (1996). (Pubitemid 26231989)
94. Zama, I. N. et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116, 5400-5406 (2010).
95. Schifitto, G. et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66, 919-921 (2006). (Pubitemid 43739773)
96. Kramer, O. H., Knauer, S. K., Zimmermann, D., Stauber, R. H. & Heinzel, T. Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 27, 732-740 (2008). (Pubitemid 351186315)
97. Swoboda, K. J. et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS ONE 4, e5268, (2009).
98. Kelly, T. K., De Carvalho, D. D. & Jones, P. A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28, 1069-1078 (2010).
99. Grant, C. et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther. 10, 997-1008 (2010).
100. Olsen, E. A. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 3109-3115 (2007). (Pubitemid 47218059)
101. Vansteenkiste, J. et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs 26, 483-488 (2008).
102. Modesitt, S. C., Sill, M., Hoffman, J. S. & Bender, D. P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109, 182-186 (2008).
103. Klimek, V. M. et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14, 826-832 (2008). (Pubitemid 351231166)
104. Schrump, D. S. et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin. Cancer Res. 14, 188-198 (2008). (Pubitemid 351377995)
105. Nagji, A. S., Cho, S. H., Liu, Y., Lee, J. K. & Jones, D. R. Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. Mol. Cancer Ther. 9, 2834-2843 (2010).
106. Chen, C. S., Weng, S. C., Tseng, P. H. & Lin, H. P. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879-38887 (2005).
107. Traynor, A. M. et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. J. Thorac. Oncol. 4, 522-526 (2009).
108. Garber, K. HDAC inhibitors overcome first hurdle. Nat. Biotechnol. 25, 17-19 (2007). (Pubitemid 46087886)
109. Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007). (Pubitemid 46686474)
110. Miranda, T. B. et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
111. Zhou, J. et al. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118, 2830-2839 (2011).
112. Cha, T. L. et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 310, 306-310 (2005).
113. Shi, L. et al. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl Acad. Sci. USA 108, 7541-7546 (2011).
114. Duns, G. et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70, 4287-4291 (2010).